Gastrointestinal transit and 5‐ASA release from a new mesalazine extended‐release formulation

Abstract

The administration of the new mesalazine formulation was well tolerated, and 5-ASA was continuously released along the whole colon, a favourable prerequisite for the therapy of distally located inflammatory bowel disease.